Understanding the GLP-1 Receptor Family

The “GLP-1 receptor family” in metabolic peptide research usually refers to four related receptors: GLP-1R, GIPR, glucagon receptor, and (less commonly) GLP-2R. They share structural homology and a common evolutionary ancestor — but their pharmacology diverges in ways that explain modern drug-engineering strategies.

The four receptors

GLP-1 receptor (GLP-1R)

• Class B G-protein coupled receptor
• Expressed on pancreatic beta cells, central satiety neurons, gastric tissue
• Native ligand: GLP-1 (glucagon-like peptide-1)
• Signals primarily through Gαs / cAMP, with β-arrestin recruitment
• Targeted by: liraglutide, semaglutide, exenatide

GIP receptor (GIPR)

• Class B GPCR, structurally similar to GLP-1R
• Expressed on pancreatic beta cells, adipose tissue, CNS
• Native ligand: GIP (glucose-dependent insulinotropic polypeptide)
• Signals through Gαs / cAMP
• Targeted by: tirzepatide (dual GLP-1/GIP)

Glucagon receptor (GCGR)

• Class B GPCR, related to GLP-1R and GIPR
• Expressed on hepatocytes (primary), adipose tissue
• Native ligand: glucagon
• Signals through Gαs / cAMP
• Targeted by: retatrutide (triple agonist) and other emerging therapeutics

GLP-2 receptor (GLP-2R)

• Class B GPCR
• Expressed primarily on intestinal mucosa
• Native ligand: GLP-2
• Used in different therapeutic context (intestinal-tissue research, short bowel syndrome)
• Targeted by: teduglutide

The dual / triple agonist strategy

The reason this receptor family is interesting to modern peptide engineering: their structural similarity means a single peptide backbone can be engineered to activate two or even three of them at the same time.

• Single agonist (semaglutide → GLP-1R only): the original metabolic-peptide strategy
• Dual agonist (tirzepatide → GLP-1R + GIPR): clinically validated; outperforms single-agonist on weight endpoints
• Triple agonist (retatrutide → GLP-1R + GIPR + GCGR): in clinical trials; early data suggests further metabolic gains

The dose-response logic: each receptor adds a different metabolic dimension. GLP-1R signals beta-cell and central satiety effects. GIPR adds adipose-tissue regulation. GCGR adds hepatic effects. Activating more of them at once expands the metabolic surface the drug can act on.

Biased agonism — a subtler dimension

Even within a single receptor, ligands can bias downstream signaling between Gαs (cAMP-based) and β-arrestin pathways. Tirzepatide, for example, is a “biased” agonist at the GLP-1 receptor — it preferentially recruits the cAMP arm. This is thought to contribute to the more favorable tolerability profile relative to balanced GLP-1 agonists at equipotent metabolic doses.

The biased-agonism dimension is where most current peptide-engineering effort is concentrated. The receptor-count question is largely answered (more is better, within engineering tractability). The signaling-bias question is where the differentiation lives.

Sourcing implications

For research programs studying this receptor family:

• Reference standards for each ligand should be available with full per-lot documentation
• Mass-spec data is particularly important — the fatty-acid conjugation on these molecules complicates identity confirmation
• Counter-ion choice (acetate vs TFA) matters more for receptor-binding assays where TFA can interfere